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In 2014, the European Committee for Medicinal Products for
Human Use (CHMP) published a draft regulatory guideline for the
evaluation of influenza vaccines. Following a public consultation
round, the final guidance will be published in the near future. Here,
we highlight the main changes in the clinical section in this guideline
and discuss the background to these changes and whether the new
consolidated guidance document can be expected to achieve a better
understanding of the performance of seasonal, zoonotic and
pandemic influenza vaccines during the regulatory licensing process.
The new influenza guideline reflects a changed approach to the
regulatory assessment of influenza vaccines, resulting in the
abolition of serological criteria, known as the CHMP criteria, which
have been the mainstay for evaluating the influenza vaccine
immunogenicity for several decades. The new guideline adopts a
more diversified approach to the measurement and reporting of the
immune response to influenza vaccines and sets a requirement to
conduct clinical outcome trials in young children. Importantly,
more emphasis is placed on the post-licensure monitoring of the
benefit risk of influenza vaccines, including a request for continuous
monitoring of efficacy and enhanced safety surveillance. Despite the
improvements these new requirements will expectedly bring to the
regulatory assessment of influenza vaccines, major challenges remain
which cannot be overcome by new guidance alone. Ongoing
initiatives in which academia, manufacturers, public health
institutes and regulators work together to address these challenges
are central to the development of robust tools to evaluate and
monitor performance of influenza vaccines in the future.
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Introduction
In 2014, the European Committee for Medicinal Products for
Human Use (CHMP) published a draft regulatory guideline
for the evaluation of influenza vaccines.1 This guideline is
intended to update the multitude of guidance documents in
Europe which cover quality, and non-clinical and clinical
regulatory requirements for seasonal, zoonotic or pandemic
vaccines into a consolidated guidance document for the
development of new influenza vaccines.
As outlined in a concept note published in 2011,2 the use
of influenza vaccines is in certain aspects based upon “long-
standing practices rather than rigorous scientific appraisal”.
The experience gained from the influenza A(H1N1)2009
pandemic brought into question the validity of several
aspects of the existing regulatory guidelines. In particular, the
assessment of the immune response, which focuses on
haemagglutination inhibition (HI) and single radial haemol-
ysis (SRH) assays, was considered to be in need of revision.3
Furthermore, a lack of understanding of the effect of
vaccination on certain subpopulations, such as young
children, called for improvements to existing guidelines.3,4
In this article, we highlight the main changes in the clinical
section of the new influenza guideline and their scientific
background, and discuss whether this consolidated guidance
document can be expected to achieve a better understanding
of the performance of seasonal, zoonotic and pandemic
influenza vaccines during the regulatory licensing process.
We consider the evidence and current understanding
surrounding the evaluation of the immune response, efficacy
and safety of influenza vaccines and how the proposed
guideline might improve the understanding on the effect of
influenza vaccines on different subpopulations.
European regulatory framework
In Europe, influenza vaccines are either licensed on a Europe-
wide scale where all Member States are involved, referred to as
a ‘central procedure; via procedures in which selectedMember
States are involved, referred to as “decentralized procedure” or
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“mutual recognition procedure”; or on a national level. Whilst
this provides a diverse regulatory landscape, in general all
Member States adhere to scientific and regulatory guidance as
set out by the CHMP. The CHMP is the committee of the
EuropeanMedicines Agency (EMA), responsible for preparing
the Agency’s scientific opinion regarding the licensing of
human medicinal products, including vaccines. Regulatory
guidelines, such as the new influenza guideline, inform
industry on the minimum requirements for licensing of new
medicinal products. They reflect the information needed to
determine the benefit risk balance of a product and to
adequately describe the characteristics of the product to ensure
safe and effective use. In the drafting of these guidelines, the
CHMP is supported by several expert groups, such as the
Vaccine Working Party and the Biologics Working Party. The
Pharmacovigilance Risk Assessment Committee (PRAC) is the
committee of the EMA responsible for the assessment and
monitoring of safety issues that arise post-licensure.
The newly revised influenza guideline distinguishes three
types of influenza vaccines: those aimed at protecting
individuals against seasonal, annually recurring influenza;
zoonotic vaccines that contain an influenza virus strain of
animal origin and which were previously referred to as pre-
pandemic vaccines; and pandemic influenza vaccines which
are intended for use in a pandemic and which include
pandemic preparedness vaccines, formerly referred to as
pandemic mock-up vaccines. The revised guideline integrates
recommendations for new influenza vaccines; however, it
clearly indicates that it does not intend to cover novel
constructs, for example vaccines targeted at epitopes other
than those on the haemagglutinin stalk.
Serological correlates of protection:
moving away from the existing paradigm
for establishing efficacy of influenza
vaccines
Traditionally, efficacy of inactivated influenza vaccines for
regulatory assessment in Europe has been estimated through
the determination of immunogenicity with serological assays.
This assessment focused primarily on the HI assay for which
seroprotection was defined as a cut-off of HI ≥ 1:40, or the
SRH assay for which a zone area of 25 mm2 is defined as a
protective threshold. These cut-offs stem from limited data
from challenge studies conducted decades ago, demonstrat-
ing a relationship between HI titres and infection rates. These
studies found that a pre-challenge serum HI titre of 18–365
measured by HI assays or 42–446 measured by SRH assay
correlated with 50% protection against infection. The
serological response would be assessed by applying a set of
criteria commonly referred to as the CHMP criteria
(Table 1). For the annual variation of influenza strains in
seasonal inactivated vaccines, one or more of the CHMP
criteria had to be met. For pandemic vaccines, all three of the
criteria had to be met.
There has been a growing recognition that relying on a
single serological cut-off for determining the benefit of
different influenza vaccines for different subgroups and
different vaccine constructs is not the most informative
approach7 and that the appropriateness of the defined
correlate of HI ≥ 1:40 can be questioned.3,8–10
Challenge studies on which the protective thresholds are
based were performed in healthy adults with attenuated
strains.5 However, influenza vaccines are intended not only
to protect healthy adults but also to protect vulnerable
children, older adults and adults with underlying comor-
bidities against consequences of natural infections with
virulent influenza strains. Whether the correlates established
in these challenge studies5 can be transferred to these
situations has not been established. For example, one study
identified that in children, an HI titre >1:110 would predict
50% of clinical protection and a titre of 1:330 would predict
80% of protection.11 A second study could not consistently
predict protection with HI titres in healthy adults,8 and in
older adults, it has been suggested that cell-mediated
immunity (CMI) rather than humoral immunity would be
associated with protection.12 Serological assays are not an
appropriate measure for the assessment of immunity against
live attenuated influenza vaccines.9
Nonetheless, for decades the regulatory assessment of
vaccines has relied on these criteria and correlates of
protection even though their suitability to the situations
for which they have been applied has not been established.
The use of these correlates has arguably resulted in a loss of
opportunity to gain knowledge and understanding of the
functioning of influenza vaccines. Moreover, presenting and
communicating study results against these criteria may have
led to a false sense of security from the impression that a
vaccine will convey a level of protection in the target
population, when in fact this has not been established. The
Table 1. European CHMP criteria for evaluation of influenza vaccine
immunogenicity
Adults
Older adults
(>60 years)
GMT increase 25 2
Seroconversion/significant increase* 40% 30%
Seroprotection* 70% 60%
*In HI tests, seroconversion corresponds to: negative pre-vaccination
serum (HI < 1:10), post-vaccination serum HI ≥ 1:40; pre-vaccination
serum >1:10, significant increase: at least a fourfold increase in titre.
Seroprotection corresponds to the percentage with serum HI ≥ 1:40.
Alternative criteria have been defined for the SRH assay.
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abolishing of these criteria marks a major shift in regulatory
thinking and paves the way to a more evidence-based
approach for the assessment of vaccine performance.
A potentially more pressing problem arising from reliance
on serological assays is the lack of standardization.13,14 An
international collaborative study which evaluated assay
reproducibility for pandemic influenza H1N1 found the
interlaboratory variation in the HI and virus neutralisation
(VN) assay to be up to sixfold and sevenfold, respectively,15
whilst interlaboratory variation has been found up to 80-fold
for HI assays and 109-fold for VN assays.16 This forms a clear
impediment to reliance on these serological assays for the
determination of efficacy. Comparisons of vaccine perfor-
mance between different studies, including those performed
in different seasons, cannot be made, limiting the accrual of
understanding in the performance of different vaccines.
In response to these issues, the new guideline firstly
requests a more diversified characterisation of the immune
response and secondly the guideline no longer relies on
serological assays with a predefined protective threshold to
establish benefit.
Requirements on immunogenicity
The guideline requests a more comprehensive package on the
immunogenicity which includes – next to quantifying the
HA antibody response – quantifying functional antibodies by
determining neutralising antibody titres with VN assays and
assessing the CMI in a subset of trial participants, in
particular in older adults.
All these assays come with limitations. The VN assay is
considered a suitable alternative to HA-based assays3;
however, the optimal protocol for this assay is yet to be
identified.
Although the assessment of CMI is regarded as an
integral part of the characterisation of the immune
response to influenza vaccination and should therefore be
performed for every new vaccine,17 the difficulty is in
deciding what to measure, when to measure and how to
measure and it is here that the guideline lacks specificity.
Here too, a clear correlation with protection has not been
established and the interpretation of results will be
challenging. As the scientific understanding of the mech-
anisms through which CMI conveys protection evolves, so
will the ability to set clear requirements and to determine
what aspects of CMI can best be used to characterise the
immune response and bring understanding to the level of
protection that vaccines can elicit in different target groups.
Until such time, regulators, manufacturers and scientists
will need to maintain a dialogue to improve the charac-
terisation of influenza vaccines.
The guideline additionally states that the neuraminidase
antibody (NA) response to vaccination should be determined
where appropriate. NA has been found to play a role in the
prevention of clinical disease, whereas HA inhibits infection
and viral replication.18–22 As, ultimately, influenza vaccina-
tion aims at preventing clinical disease, insight into the NA
response for new influenza vaccines could be an important
step in achieving a better characterisation of the clinical
characteristics of influenza vaccines. However, the amount of
NA is not standardised in current influenza vaccines.
Therefore, for these vaccines, it does not make sense to
determine the NA response, however should be considered in
the development of future influenza vaccines.
The challenges regarding assay standardization apply to all
these assays mentioned. Certain measures are proposed to
minimise the impact, for using using a single centralised
laboratory, employing validated assays and international
standards where available, and using in-house controls and
unified protocols. Although some of these may prove
logistically challenging, the variability in assays necessitates
these steps. It would be impossible, for example, to rely on
different laboratories to analyses samples from a single study.
Ongoing research and collaboration between public health
institutes, regulators, manufacturers and academia focussing
on the standardisation and development of assays can be
expected to result in improved assays and assay reproducibil-
ity.23
A consequence of abandoning the CHMP criteria is a
change to the requirements in the presentation of immuno-
genicity data. Data from the SRH, HI and VN assays should
be presented according to geometric mean titres (GMTs) and
reverse cumulative distribution curves (RCDCs). In addition,
seroconversion rates should be given. As there is no set
definition for seroconversion, several definitions could be
applied when presenting the data. GMTs are a summary
measure which can be useful in comparing responses
between two groups. The RCDCs will allow the visualisation
of the immune response across the population. These
changes will allow for a more comprehensive assessment of
the vaccine-induced immune response than under the
former guideline, which often resulted in the simple conclu-
sion 0The CHMP criteria were met0.
How to establish clinical efficacy in the
post-CHMP criteria era?
As stated earlier, serological data alone will no longer be
sufficient to conclude whether a vaccine is protective in the
target population. The new approach for seasonal and for
zoonotic and pandemic vaccines is outlined below.
Seasonal vaccines
For persons over 18 years of age, the proposed guideline
states that efficacy of seasonal, non-adjuvanted inactivated
vaccines can be determined in a direct head to head
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comparison either with a licensed vaccine or with a similar
construct for which there is “at least some data to support
effectiveness”. If the immune response of the new vaccine is
non-inferior, it is thought reasonable to assume the protec-
tive efficacy would at least be comparable.
For children younger than 3 years, there is inconsistent
evidence on the efficacy and effectiveness of seasonal
inactivated vaccines.24,25 Efficacy in this age group cannot
be assumed for existing vaccines and cannot therefore be
deduced from comparative immunogenicity studies. Hence,
the proposed guideline requires applicants to conduct
randomized controlled trials with clinical endpoints in order
to conclude efficacy for children aged 6 months to 3 years.
For children between the ages of 3–6 years, there is some
evidence to support efficacy of inactivated influenza vaccines,
albeit being moderate.24–26 Yet the proposed guideline states
that as the proportion of children up to the age of
approximately 9 years who are immunologically primed is
thought to be variable, efficacy can be deduced from
demonstrating a non-inferior immune response to the
youngest children for whom efficacy against clinical end-
points should have been demonstrated. For children over the
age of nine, the approach taken in the proposed guideline is
similar to the approach in adults.
Zoonotic vaccines and pandemic vaccines
Zoonotic and pandemic vaccines pose a regulatory challenge.
Prior to licensure, it is not possible to obtain efficacy data,
and the clinical package will be limited to immunogenicity
and safety data. Moreover, ethical considerations of testing
vaccines in human subjects when there is no direct benefit to
the recipient, as there is no immediate threat of a circulating
virus, certainly have an impact on regulatory expectations.
No firm requirements are set for children, it is merely stated
that immunogenicity and safety data in this age group should
be obtained “as far as may be possible”.
Requirements regarding annual changes in
seasonal inactivated vaccines
For seasonal influenza vaccines, the annual change in
composition has always posed a unique challenge, that is
how to determine the impact of the change in viral strains on
the clinical characteristics of the vaccine in a short timeframe
between production and epidemic. There has been a
substantial shift in the proposed guideline. Previously, the
CHMP required manufacturers of inactivated influenza
vaccines to conduct small clinical trials in 100 adults,
including 50 subjects aged ≥60 years, to demonstrate that
immunogenicity and reactogenicity were not affected by the
strain change.
These trials are not able to detect changes in the clinical
characteristics of influenza vaccines.27 More importantly
however, it is unlikely that a change in vaccine strains as a
result of antigenic drift will affect the clinical characteristics
of these vaccines to such a degree that the benefit risk balance
is radically altered. Consequently, these trials are no longer
required. The proposed guideline and an earlier published
annex to this guideline28 instead move towards closer
monitoring of seasonal influenza vaccine performance.
Moving towards sustainable monitoring of
vaccine performance
Effectiveness
For all seasonal influenza, vaccines licensed in Europe a Risk
Management Plan (RMP) will be required which should
include the monitoring of influenza vaccine effectiveness
(IVE).
From a regulatory perspective, the monitoring of IVE
would fit into the lifecycle approach of medicines. It will
inform the evolution of the benefit risk balance, allow the
detection of potential issues with effectiveness and provide
data on the benefits to balance potential safety issues. In
addition, once well established, these routine studies could
provide a platform to address questions surrounding the
performance of new influenza vaccines that are difficult to
address pre-licensure, and to measure product-specific
effectiveness in a pandemic.
Observational studies into IVE are notoriously subject to
bias,29 and the success of this measure will depend on the
robustness of the study protocols and implementation
thereof. Moreover, studies should ideally be capable of
reporting effectiveness estimates in a timely manner and
provide brand-specific estimates, potentially challenging the
feasibility of this exercise.
The proposed guideline builds upon experience already
gained in the field through initiatives such as the European I-
MOVE collaboration30 and encourages manufacturers to tap
into this experience and use existing networks. It refers to
protocols developed by the European Centre for Disease
Control (ECDC). These include (test negative) case–control
studies, cohort studies and screening studies. Influenza cases
have to be laboratory confirmed via either RT-PCR or
culture, although within the cohort design, non-specific
endpoints such as medically attended influenza like illness,
all-cause deaths, intensive care admissions and hospitalisa-
tions for all respiratory conditions are considered endpoints
of interest. When conducting a cohort study, the guideline
requires a nested (test negative) case–control study to
confirm the effectiveness against laboratory-confirmed
influenza, ensuring a specific measure of effectiveness is
available. For details on most aspects, the guideline refers
back to the ECDC protocols.
The measurement of IVE is a challenging undertaking, and
it should not be the expectation that requested studies will
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provide clear answers during the first few years. The
landscape of vaccination in Europe is diverse, and although
this diversity can be an advantage when evaluating vaccines,
it will prove a challenge when implementing IVE monitoring.
Not only will the epidemiology differ between regions,
vaccination policies vary between countries as does the
uptake of vaccines and vaccines used. Moreover, vaccination
registries are not operational in all countries and regions
within the EU.31 Where they are in place, it is not always
possible to link these to outcome data such as electronic
healthcare data. This will certainly limit the initial ability to
conduct larger scale studies that could provide product-
specific estimates in selected target groups.
It is important to realise that IVE is not only a
consequence of the product used but of a range of
determinants such as the vaccination programme and viral
epidemiology which play an important role. Any estimates
obtained will have to be placed within the context of the
myriad determinants of IVE, many of which are poorly
understood. This underlines the shared responsibilities
between manufacturers, public health institutes and regula-
tors in evaluating and assessing vaccine effectiveness.
Safety
The monitoring of safety is central to the monitoring of
vaccine performance. In Europe, routine pharmacovigilance
activities are currently the main source for the identification
of potentially serious but rare adverse events following
influenza vaccination, and they rely heavily on passive
reporting. This comes with limitations as it does not allow
for estimation of the incidence of specific adverse events or
the association with vaccination. Although the safety of
inactivated influenza vaccines that have been used over
recent decades is well characterised,26,32,33 there is always the
possibility of serious adverse events occurring following
manufacturing changes, contamination of batches or
through the introduction of new pandemic influenza strains.
Moreover, the introduction of new influenza vaccines would
necessitate intensive surveillance of their safety as clinical
trials are insufficient to detect rare but serious adverse
events.
Whilst some European countries have the infrastructure in
place to rapidly evaluate safety signals, this capacity is
fragmented. Moreover, countries are often too small, or
vaccine use is too limited, to properly evaluate rare safety
signals. As mentioned earlier, vaccination registries do not
exist in all countries and regions of Europe, and it is not
always possible to link vaccination data to outcome data.31
With an increasing need for rapid evaluation of safety signals
in order to provide timely guidance to policymakers and
address public concerns, there is a clear need to invest further
in European systems to monitor and evaluate the safety of
vaccines.
The proposed guideline requires that the RMP includes
plans for enhanced surveillance of vaccine safety, as detailed
in an Annex to the guideline.28 The aim of this enhanced
surveillance is to rapidly detect a significant increase in
reactogenicity that would signal potential serious risks
following annual strain changes. Adverse events of interest
include typical local and systemic reactions to vaccination
such as rash, injection site reactions, myalgia, fever, nausea
and headache. To achieve this, defined cohorts of children
and adults, including a minimum total of 500 persons–100
per age stratum, should be followed after vaccination for the
occurrence of several adverse events of interest. Rates of
adverse events will have to be compared to rates in previous
years. Alternatively, enhanced passive surveillance could be
employed in which the reporting of adverse events is
facilitated to obtain reporting rates which can function as a
surrogate for the adverse events of interest. Furthermore,
data mining of electronic health record data can be also
employed. However, such mining has the clear limitation of
the near impossibility of gathering information on vaccine
reactogenicity from electronic healthcare databases.
Although the increased attention to the monitoring of
influenza vaccine safety is welcomed, it is questionable
whether the proposed enhanced surveillance is the most
efficient means to achieve the goal; the rapid identification of
safety signals has the ability to thoroughly evaluate the
association between the signal and vaccination. It would
seem more sensible to further invest in the creation of
vaccine registries in Europe, improve the registration of
vaccination data in existing registries, facilitate the linkage of
these registries to electronic healthcare databases, limit the
data lag for registries and databases and invest in the capacity
to implement rapid signal detection and evaluation. Such an
infrastructure would permit continuous monitoring and
evaluating the safety of influenza vaccines, also after annual
strain changes. It is unlikely that data on vaccine reacto-
genicity in 500 persons will be predictive of any serious but
rare adverse events and whether the studies will be able to
discriminate relevant changes from year to year that could
predict adverse events which could alter the BR balance of
the vaccines.
The 2014/2015 influenza season was the first season for
which the enhanced surveillance should have been up and
running, and time will tell how suitable these studies are in
detecting potential safety signals associated with the updating
of influenza strains in seasonal vaccines.
Final considerations
Lessons learned during the influenza A(H1N1)2009 pan-
demic together with advances in the scientific understanding
of influenza and the immune response to influenza viruses
and vaccines have resulted in the revision of existing
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regulatory guidelines for the licensing of influenza vaccines in
Europe. Following a public consultation round, it is expected
that the final guidance will be published in the near future.
The proposed guideline reflects a changed approach to the
regulatory assessment of influenza vaccines. This has resulted
in the abolition of the CHMP criteria, the introduction of
more diversified requirements for measuring and reporting
the immune response to influenza vaccines, and the
requirement for all new influenza vaccines to conduct trials
with clinical outcomes in children aged 6–36 months.
Furthermore, immunogenicity data are no longer requested
to support annual strain changes. Importantly, more empha-
sis is placed on the post-licensure monitoring of the benefit
risk of influenza vaccines, including a request for continuous
monitoring of efficacy and enhanced safety surveillance.
Presently, several gaps remain in the understanding of the
performance of seasonal influenza vaccines. It is expected
that the changes made to the influenza guideline will
improve the characterisation of clinical characteristics of
new and existing influenza vaccines. The new requirements
will certainly improve our knowledge on the functioning of
influenza vaccines in children and can be expected to provide
a better insight into the immune response overall. The move
towards sustained monitoring of the benefits and risks of
influenza vaccines underlines regulation does not stop at
licensure, and will undoubtedly lead to more accurate data
on the benefits and risks to address public concerns should
these arise.
Major challenges, however, remain, such as the absence of
standardised serological assays and the absence of a correlate
of protection to facilitate vaccine evaluation. Moreover, the
limited availability of an infrastructure in Europe which
would allow timely and consistent evaluation of the effec-
tiveness and safety of vaccines currently impedes adequate
benefit risk monitoring of new influenza vaccines. New
guidance cannot overcome these challenges, and regulators
can merely encourage investment in improved methods.
Manufacturers are responsible for their products, regula-
tors guard those products, and public health institutes are
responsible for the programmes in which the vaccines are
used. Improving the evaluation of vaccines is therefore a
shared responsibility between manufacturers, regulators and
public health institutes – all of which are dependent on
academia for scientific input. This recognition, in addition to
the identified need for improved methods and collaboration
for vaccine evaluation, has resulted in EU-wide collaboration
between public health institutes, industry, regulators and
academia which aims to improve the benefit risk monitoring
of vaccines34 and serological assays for evaluating influenza
vaccines.23 Collaborative initiatives like these will ultimately
result in improved vaccines a better understanding of their
immunology and clinical performance, but also more robust
tools to monitor performance of influenza vaccines in the
future.
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